JBC Advanced Glycation Endproducts

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M909746199 on June 13, 2000

J. Biol. Chem., Vol. 275, Issue 38, 29594-29601, September 22, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/38/29594    most recent
M909746199v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Antil-Delbeke, S.
Right arrow Articles by Ménez, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Antil-Delbeke, S.
Right arrow Articles by Ménez, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular Determinants by Which a Long Chain Toxin from Snake Venom Interacts with the Neuronal alpha 7-Nicotinic Acetylcholine Receptor*

Stéphanie Antil-DelbekeDagger , Carole GaillardDagger , Toru TamiyaDagger , Pierre-Jean Corringer§, Jean-Pierre Changeux§, Denis ServentDagger , and André MénezDagger

From the Dagger  Département d'Ingénierie et d'Etudes des Protéines, Commissariat à l'Energie Atomique Saclay, 91191 Gif-sur-Yvette, France and the § Laboratoire de Neurobiologie Moléculaire, Institut Pasteur, 75724 Paris Cedex 15, France

Received for publication, December 8, 1999, and in revised form, June 13, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Long chain curarimimetic toxins from snake venom bind with high affinities to both muscular type nicotinic acetylcholine receptors (AChRs) (Kd in the pM range) and neuronal alpha 7-AChRs (Kd in the nM range). To understand the molecular basis of this dual function, we submitted alpha -cobratoxin (alpha -Cbtx), a typical long chain curarimimetic toxin, to an extensive mutational analysis. By exploring 36 toxin mutants, we found that Trp-25, Asp-27, Phe-29, Arg-33, Arg-36, and Phe-65 are involved in binding to both neuronal and Torpedo (Antil, S., Servent, D., and Ménez, A. (1999) J. Biol. Chem. 274, 34851-34858) AChRs and that some of them (Trp-25, Asp-27, and Arg-33) have similar binding energy contributions for the two receptors. In contrast, Ala-28, Lys-35, and Cys-26-Cys-30 selectively bind to the alpha 7-AChR, whereas Lys-23 and Lys-49 bind solely to the Torpedo AChR. Therefore, alpha -Cbtx binds to two AChR subtypes using both common and specific residues. Double mutant cycle analyses suggested that Arg-33 in alpha -Cbtx is close to Tyr-187 and Pro-193 in the alpha 7 receptor. Since Arg-33 of another curarimimetic toxin is close to the homologous alpha Tyr-190 of the muscular receptor (Ackermann, E. J., Ang, E. T. H., Kanter, J. R., Tsigelny, I., and Taylor, P. (1998) J. Biol. Chem. 273, 10958-10964), toxin binding probably occurs in homologous regions of neuronal and muscular AChRs. However, no coupling was seen between alpha -Cbtx Arg-33 and alpha 7 receptor Trp-54, Leu-118, and Asp-163, in contrast to what was observed in a homologous situation involving another toxin and a muscular receptor (Osaka, H., Malany, S., Molles, B. E., Sine, S. M., and Taylor, P. (2000) J. Biol. Chem. 275, 5478-5484). Therefore, although occurring in homologous regions, the detailed modes of toxin binding to alpha 7 and muscular receptors are likely to be different. These data offer a molecular basis for the design of toxins with predetermined specificities for various members of the AChR family.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Venoms of elapid and hydrophid snakes contain a family of small toxic proteins called curarimimetic toxins or alpha -neurotoxins that bind with high affinity to muscular nicotinic acetylcholine receptors (AChRs)1 and hence affect synaptic transmission (1, 2). All these toxins adopt a leaf-like shape with three adjacent loops rich in beta -sheet that emerge from a small globular core where four disulfide bonds are invariably located (3-7). Notwithstanding their common fold and their similar biological function, alpha -neurotoxins are currently classified as short chain toxins with 60-62 residues and four disulfide bonds and long chain toxins with 66-74 residues and five disulfide bonds. In agreement with this old chemically based classification, we recently showed that the long chain toxins are also and uniquely capable of binding with high affinity to the neuronal alpha 7 receptor (8). These preliminary data also indicated that the neuron-specific binding capacity may be associated with the unique presence in the long chain toxins of a small cyclic loop at the tip of their central loop. The goal of this work was therefore to identify as precisely as possible the determinants by which long chain toxins bind to the neuronal alpha 7-AChR and to compare them with those involved when toxins bind to the muscular AChR.

The toxin used in this study is alpha -cobratoxin (alpha -Cbtx) (9) from Naja naja siamensis (probably Naja kaouthia (10)). It is a prototype of long chain curarimimetic toxins with a single polypeptide chain of 71 amino acids and five disulfide bonds. alpha -Cbtx binds with high affinity to the muscular type AChR from Torpedo marmorata (Kd = 58 pM) and the neuronal alpha 7-AChR (Kd = 9 nM). Its three-dimensional structure is known from both NMR (11) and x-ray crystallographic studies (12). We recently submitted this toxin to an extensive site-directed mutagenesis and found that the residues by which it binds to the Torpedo AChR include a number of amino acids that are highly conserved throughout the family of curarimimetic toxins (13). These are Lys-23, Trp-25, Asp-27, Phe-29, and Arg-33, which belong to the concave face of the toxin loop II, and Lys-49, which belongs to the same face of loop III. The same residues of a short chain curarimimetic toxin are involved in binding to the same AChR (14, 15). In addition, however, long and short chain curarimimetic toxins use specific residues for binding to the Torpedo AChR. These specific residues are located in the C-terminal tail and in loop I of long and short chain toxins, respectively (13).

The goal of this study was 3-fold. First, using a set of 36 toxin mutants, we identified the residues by which alpha -Cbtx most likely binds to the neuronal alpha 7 receptor. Second, we compared these data with those that previously indicated the residues by which the same toxin binds to the Torpedo AChR (13). Third, to identify the regions of the alpha 7 receptor that are recognized by the toxin, we mutated different residues in various functional loops of the alpha 7 receptor and studied the effect of these mutations on toxin binding. Using a double mutant cycle approach, we then studied the possible proximity between receptor Tyr-187 and toxin Arg-33. This choice was based on previous findings that the homologous Tyr-190 of the alpha  subunit of the muscular receptor is close to Arg-33 of another curarimimetic toxin (16). We also investigated other possible interactions between toxin Arg-33 and other receptor residues, including Trp-54, Leu-118, and Asp-163, whose homologs in the muscular receptor were observed to be in proximity to Arg-33 of another toxin (17). Together, our data strongly suggest the following. (i) Toxin binding presumably occurs in homologous regions of the muscular type AChR and the neuronal alpha 7-AChR; however, the detailed modes of binding to both receptor subtypes are likely to be different. (ii) The same core of six residues (Trp-25, Asp-27, Phe-29, Arg-33, Arg-36, and Phe-65) is involved in the binding to both subtypes of AChRs. (iii) Three of these common residues (Phe-29, Arg-36, and Phe-65) contribute differently to the binding energy for the two AChRs. (iv) A number of additional residues are associated with the specific recognition of each receptor subtype. These are Ala-28, Lys-35, and Cys-26-Cys-30, which bind selectively to the neuronal AChR, and Lys-23 and Lys-49, which bind solely to the muscular type receptor. These results offer an explanation as to how a toxic protein recognizes two members of a receptor family and provide a molecular basis for the design of new toxins that may be more specific to these and other subtypes of the AChR family.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression, Purification, and Characterization of Recombinant alpha -Cobratoxin-- Wild-type and mutant recombinant alpha -cobratoxins were obtained as described previously (13). Briefly, cDNA encoding Cbtx was cloned into the pCP vector (18) and expressed as a fusion protein in Escherichia coli strain BL21(DE3). The fused toxin was purified on an IgG-Sepharose column, cleaved by CNBr, refolded with 4 mM GSH and 2 mM GSSG, and purified on a reverse-phase C4 column. The alpha -Cbtx mutants described here were prepared using the QuickChangeTM kit (Stratagene), and the sequence of the entire gene was checked by automatic sequencing (ABI PRISMTM 310 genetic analyses, (Perkin-Elmer Applied Biosystems). Biochemical and biophysical characterization of each mutant was assessed by (i) SDS-polyacrylamide gel electrophoresis with silver staining, (ii) analytical reverse-phase high performance liquid chromatography (Vydac C4 5-µm column, 0.46 × 25 cm), and (iii) electrospray mass spectroscopy and circular dichroic analysis as described previously (13). The concentration of purified Cbtx was determined by measuring the absorbance at 278 nm of a given solution of toxin and by amino acid analysis.

Expression of Wild-type and Mutant alpha 7 Receptors in Human Embryonic Kidney (HEK)-293 Cells-- A chimeric cDNA of a neuronal type nicotinic receptor (alpha 7/5-HT3) was transfected into HEK-293 cells by calcium precipitation as described previously (8, 19, 20). Two days after the transfection, the cells were harvested in phosphate-buffered saline with 5 mM EDTA, washed two times with phosphate-buffered saline, and finally resuspended in 3 ml of this buffer/plate for the binding experiments. The receptor mutants were obtained using the QuickChangeTM kit according to the instructions of the manufacturer, and their sequences were checked by sequencing.

Binding Assays-- The affinities of the toxins for the alpha 7/5-HT3 receptor were determined as described previously (8, 21) with slight modifications. Competition experiments showed the effect of wild-type and mutant recombinant alpha -cobratoxins on the initial rate of 125I-bungarotoxin (Bgtx) binding. Different concentrations of alpha -Cbtx were preincubated for 4.5 h with cells suspended in phosphate-buffered saline and filtered 6 min after the addition of 5 nM 125I-Bgtx. This preincubation time was checked to be sufficient to reach equilibrium binding between wild-type or mutant toxins and the receptor (no change after overnight preincubation). Furthermore, the association and dissociation kinetics of 125I-Bgtx for the Y187F receptor mutant were determined and showed that no significant dissociation of the tracer occurred during the 6-min time of the assay and that, after this time, the rate of association of 125I-Bgtx was still linear. The protection constant (Kp) calculated by fitting the competition data to the empirical Hill equation was shown to correspond to the dissociation constants (20, 22).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Preparation and Characterization of Wild-type and Mutant alpha -Cobratoxins-- Recombinant alpha -Cbtx was produced as a fusion protein in E. coli as described previously (13). The final yield of toxin after purification, cleavage, and refolding reached ~1.5 mg/liter of culture.

To identify the residues by which alpha -Cbtx binds with high affinity to the neuronal alpha 7 receptor, we produced 36 mutants and hence probed the role of 34 of its 71 residues. The explored positions included all the residues of the toxin loop I, from Phe-4 to Asp-13. They also included all residues (Tyr-21, Lys-23, Trp-25, Arg-36, and Asp-38) of the concave face of loop II, the two faces being defined by the large beta -sheet that encompasses the three toxin loops. We also explored Lys-35 in loop II, which points toward the other direction, and all residues at the tip of loop II, from Asp-27 to Arg-33, including the disulfide bond Cys-26-Cys-30. Three residues of loop III (Thr-47, Lys-49, and Asp-53) and two residues of the C-terminal tail (Phe-65 and Pro-66) were also investigated. Finally, the role of the C-terminal fragment was further explored by deleting the five last residues (mutant Delta 66). The final yield of toxin after purification, cleavage, and refolding varied between 0.5 and 1.5 mg/liter of culture. The far-UV CD spectra of all mutants were virtually superimposable with that of the venom-purified or wild-type recombinant alpha -Cbtx (data not shown). Also, the mass of each mutant, as determined by electrospray mass analyses, was identical, within experimental error, to the theoretical calculated mass (data not shown). Therefore, the wild-type and mutant recombinant toxins displayed all the expected physicochemical characteristics.

Affinities of Wild-type alpha -Cbtx for the Neuronal alpha 7 Receptor-- We investigated the capacity of wild-type and mutant toxins to inhibit the binding of 125I-Bgtx to a recombinant form of a chimeric version of the chicken alpha 7 receptor. In this version, the extracellular part of the neuronal alpha 7-type receptor was fused to the membrane and cytoplasmic regions of the 5-HT3 receptor (19). This chimeric construction allowed efficient expression in HEK-293 cells and behaved like the wild-type alpha 7 receptor in many respects (19), including its capacity to be selectively blocked by various long chain curarimimetic toxins (8).

A number of typical inhibition binding curves obtained with different alpha -Cbtx mutants are shown in Fig. 1. Binding affinities of alpha -Cbtx for neuronal alpha 7 receptors were deduced from the inhibition binding curves and were fitted to the Hill equation. We commonly found Hill coefficients equal to 1.15 ± 0.25, which suggests a homogeneous class of toxin-binding sites, in agreement with the homopentameric nature of the alpha 7 receptor. The protection constants (Table I) derived from these curves have been suggested to correspond to apparent Kd values (22). Therefore, wild-type recombinant alpha -Cbtx and the venom toxin are characterized by virtually identical Kd values of 9 ± 3 and 7.5 ± 1.5 nM, respectively. This result further confirms the identity of the recombinant and venom toxins.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   Equilibrium binding of wild-type and mutant alpha -cobratoxins to the alpha 7/5-HT3 receptor. Competition experiments showed the effect of wild-type and mutant recombinant alpha -cobratoxins on the initial rate of 125I-Bgtx binding as described under "Experimental Procedures." The continuous lines correspond to theoretical concentration responses fitted through the data points using the nonlinear Hill equation. rec, recombinant wild-type toxin.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Dissociation constants of wild-type and mutant alpha -cobratoxins for the alpha 7/5-HT3 receptor
Protection constants (means ± S.E.) were obtained from at least three different competition experiments in duplicate as described under "Experimental Procedures." Delta Delta G is the difference in free energy of binding between wild-type and mutant alpha -cobratoxins. Delta Delta G = Delta GWT - Delta GMUT = RT ln (Kd'/Kd), with R = 1.99 cal/mol/K and T = 293 K. The residues for which mutations caused an affinity decrease >5-fold (Delta Delta G > 1 kcal/mol) are indicated in boldface. Cbtx rec, recombinant wild-type toxin.

Binding Affinities of Toxin Mutants-- All residues of loop I were mutated, but none of the introduced mutations caused more than a 3-fold affinity decrease, which corresponds to a change in free energy of binding of 0.5 kcal/mol. Clearly, none of the residues of loop I individually plays a key binding role with the neuronal alpha 7 receptor (Table I).

In contrast, as many as nine residues from loop II (Trp-25, Asp-27, Ala-28, Phe-29, Cys-26-Cys-30, Arg-33, Lys-35, and Arg-36) were sensitive to mutations, with affinity decreases ranging from 5- to 340-fold (Fig. 1 and Table I). Six of these residues (Trp-25, Asp-27, Ala-28, Phe-29, Arg-33, and Arg-36) have their side chain essentially accessible from the concave face of loop II, this face being defined by the large beta -sheet displayed by the three fingers (see Fig. 4). Mutation R33E caused the greatest effect, with a decrease of 340-fold in the alpha -Cbtx binding affinity (Table I). Arg-33 may therefore be the toxin residue that contributes the most to the alpha -Cbtx-receptor recognition process. Although perhaps less critical, the other arginine of the toxin loop II (Arg-36) may also be functionally important since its mutation to alanine caused a 16-fold affinity decrease. Mutation of Trp-25 to alanine caused a weak affinity decrease, suggesting the moderate functional contribution of the indole ring. However, replacement of Trp-25 by phenylalanine or histidine had virtually no effect on toxin affinity, indicating that an aromatic side chain of variable size can be accommodated at this position (Table I). A 50-fold decrease in binding affinity was observed in mutation D27R, indicating that the presence of the bulky and positively charged arginine is unfavorable at this position. This does not mean that the presence of a negative charge at position 27 is an important element since mutation D27N caused no significant effect. More mutants are needed to understand better how Asp-27 contributes to binding. Mutation of Ala-28 to glycine caused a 5-fold affinity decrease, suggesting that a methyl group at this position may be involved in binding. Surprisingly, however, mutation of Ala-28 to arginine did not affect toxin affinity. This result suggests that position 28 can accommodate any residue whose side chain possesses some hydrophobic character. Of the three mutations introduced at Phe-29, only F29A caused an affinity decrease. This decrease was quite severe since it was associated with a binding energy change of 2.5 kcal/mol (Table I). In contrast, F29W had no effect, indicating that position 29 can accept the bulkier aromatic indole ring. It can also accommodate the hydrophobic, although not aromatic, leucine residue since mutant F29L has only a 3-fold lower affinity. Therefore, a strong hydrophobicity may be an important functional character at position 29, irrespective of whether it is brought by an aromatic or aliphatic side chain.

The other mutation-sensitive residues in loop II (Cys-26-Cys-30 and Lys-35) have their side chain accessible from the convex face of the beta -sheet. This result could indicate that mutation at any residue of the toxin loop II is followed by an affinity decrease and that our general approach may not reflect the actual binding contribution of the mutated residues. This is clearly not the case since various residues of loop II could be mutated without affecting toxin affinity. This is the case for the relatively close Asp-38, Ser-31, and Ile-32 and for the more remote Tyr-21. Therefore, the effect observed with mutations at Cys-26-Cys-30 and Lys-35 most likely indicates the involvement of these residues in binding to the receptor. The result obtained upon mutation of the two half-cystines Cys-26 and Cys-30 agrees with previous data based on reduction and chemical modification of this bond (8). However, the affinity decrease observed upon mutation is substantially less than that found upon chemical modification. That the double mutation C26S/C30S caused an affinity decrease can be interpreted in at least two nonexclusive ways. First, the deletion of the bond between residues 26 and 30 modifies the local structural constraints of the small loop, which in turn may affect the spatial positioning and hence the functional contribution of one or more of the important residues (see above) Asp-27, Ala-28, and Phe-29. However, we previously observed that mutation C26S/C30S (13) or reduction and carboxymethylation of the bond (8) caused virtually no effect on toxin binding to the Torpedo AChR, although this binding involved various residues in proximity to the disulfide bond, including Trp-25, Asp-27, and Phe-29. Therefore, we suspect that no major structural change occurred around the disulfide bond between residues 26 and 30. Second, the other explanation is that one or both of half-cystines 26 and 30 are involved in the binding to the neuronal receptor. This conclusion implies that the convex face of loop II may be functionally important. In agreement with this view, we found that Lys-35, whose side chain is accessible from the convex face of the toxin, is also functionally important, as judged from the 11-fold affinity decrease associated with its mutation to alanine. Therefore and in contrast to what was found upon binding to muscular type AChRs (13-15, 23, 24), binding to the neuronal AChR seems to involve residues located on both the concave and convex faces of the curarimimetic toxin.

Previous mutational analyses indicated the functional importance of the highly conserved Lys-23 or Lys-49 in binding to muscular receptors (13). It was not inconceivable that these residues could also be involved in binding to the neuronal receptor. However, this is not the case since inversion of their charge caused no effect on toxin affinity. Also, the two other residues (Thr-47 and Asp-53) of loop III seem to be excluded from the binding surface of the toxin, with mutations T47A and D53K causing no affinity decrease. The hydroxyl function of the invariant Tyr-21 is also unimportant since mutation Y21F had no effect on toxin affinity (Table I).

Exploration of the toxin C-terminal tail provided a rather precise answer. Mutation F65A caused a 16-fold affinity decrease, whereas mutation of the adjacent proline to alanine had no effect. Furthermore, deletion of the whole 67-71 stretch (mutant Delta 66) had no substantial effect on toxin binding affinity (Table I). Therefore, only Phe-65 seems to have a binding function. In conclusion, the work described above reveals that 10 residues (Trp-25, Asp-27, Ala-28, Phe-29, Cys-26-Cys-30, Arg-33, Lys-35, Arg-36, and Phe-65) are mutation-sensitive and may be involved in the surface by which alpha -Cbtx binds to the neuronal alpha 7 receptor, whereas a large number of surrounding residues are mutation-insensitive and hence probably excluded from the binding surface.

Mutagenesis of the Neuronal alpha 7 Receptor-- It was previously shown that the ligand-binding sites of the muscular AChR included, on one hand, three segments of the alpha  subunit surrounding Tyr-93 (loop A), Trp-149 (loop B), and between residues 180 and 200 (loop C) and, on the other hand, four regions on the gamma  and delta  subunits centered around Lys-34 (loop 1), Trp-55 (loop 2), Leu-119 (loop 3), and Asp-174 (loop 4) (reviewed in Ref. 25). By a double mutant cycle approach, residues of loops C and 2-4 of the muscular receptor were shown to be in close proximity to residues in loop II of a snake curarimimetic toxin (16, 17). We therefore explored the possibility that the homologous region in the neuronal alpha 7 receptor could also interact with alpha -Cbtx. Toward this goal, we decided to mutate five receptor residues (Tyr-187, Pro-193, Trp-54, Leu-118, and Asp-163) that are in the putative homologous loops of the alpha 7 receptor. Table II and Fig. 2 show that mutations Y187F and D163K caused 21- and 6-fold decreases in the affinity for alpha -Cbtx, respectively, suggesting that the corresponding residues are involved in toxin binding. In contrast, P193A, W54F, and L118A caused little, if any, affinity change, suggesting that they may not contribute to toxin binding. It could be argued that the observed affinity decreases could result from both a genuine affinity decrease combined with a dissociation effect of 125I-Bgtx during the time of the binding assay (6 min). Using mutant Y187F, we checked that although the dissociation rate of the toxin was significantly affected by the mutation, it did not alter the proportion of bound radioactive toxin during the 6 min of the assay (data not shown). Therefore, our data suggest the importance of the hydroxyl side chain of Tyr-187 in the toxin interaction.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Binding and coupling energies of wild-type and mutant toxins or the alpha 7 receptor
Protection constants (mean ± S.E.) were obtained from at least three experiments in duplicate as described under "Experimental Procedures." Delta Delta G is the difference in free energy of binding between wild-type (WT) and mutant toxins or receptor. Delta Delta G = Delta Gwt - Delta Gmut = RT ln(Kd(mut)/Kd(wt), with R = 1.99 cal/mol/K and T = 293 K. The coupling coefficient Omega  = Kd(wt,wt) · Kd(mut,mut)/Kd(wt,mut) · Kd(mut,wt) and values less than unity were inverted and are indicated with a minus sign. The coupling energy represents the interaction of the two mutated residues and was calculated by the equation Delta Delta Gint = RT ln(Omega ). NB, no detectable alpha -Bgtx binding.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   Inhibition of the initial rate of 125I-Bgtx binding to wild-type and mutant alpha 7 receptors expressed in HEK-293 cells by wild-type and mutant alpha -cobratoxins. A, competition binding between the Y187F receptor mutant and wild-type (WT), R33E, and F65A toxins; B, competition binding between the P193A and D163K receptor mutants and wild-type and R33E toxins; C, competition binding between the L118A and W54F receptor mutants and wild-type and R33E toxins.

We then performed a double mutant cycle analysis (16, 26, 27) using toxin mutants R33E and F65A and the different alpha 7 receptor mutants previously mentioned. In the resulting thermodynamic analysis, the difference in energy following a mutation was calculated from the following equation: Delta Delta G = Delta Delta Gwt - Delta Delta Gmut = RT ln(Kd(mut)/Kd(wt)), where wt is wild type and mut is mutant.

It is generally considered that if the Delta Delta G value obtained with both mutations is not equal to the sum of the Delta Delta G values determined for each of the two single mutations, the two mutated residues are close to each other and perhaps interacting (26), although this procedure includes some weaknesses (28). The coupling energy that reflects the energy of interaction of the two residues mutated was calculated from the equation: Delta Delta Gint = RT ln(Omega ), where Omega  = Kd(wt,wt)·Kd(mut,mut)/Kd(wt,mut)·Kd(mut,wt).

The competition binding curves obtained with the different single and double mutations are shown in Fig. 2. Table II shows the derived equilibrium dissociation constants (Kd), the free energy of binding (Delta Delta G), and the calculated values of Omega  factor and Delta Delta Gint. The coupling energies varied between 0.03 kcal/mol for Y187F/F65A and -0.86 kcal/mol for P193A/R33E. In theory, if Delta Delta Gint deviates from 0, the two mutated residues interact, and the distance between them is inversely proportional to the coupling energy value. However, a previous work (26) based on comparison of structural and mutational analyses of the barnase-barstar complex showed that many interactions observable in the structure of the complex and occurring between charged and uncharged residues separated by 4-7 Å are characterized by coupling energies ranging between 0.35 and 1.2 kcal/mol. We therefore retained the value of 0.35 kcal/mol as the threshold above which an interaction may occur.

Only two coupling values were above the threshold. These are those corresponding to the double mutants Y187F/R33E and P193A/R33E, whose coupling values are equal to -0.71 and -0.86 kcal/mol, respectively. The three other mutant pairs involving R33E in the toxin were associated with much smaller Delta Delta Gint values (ranging from 0.11 to 0.15 kcal/mol), also like the double mutant Y187F/F65A, which was characterized by a Delta Delta Gint of 0.03 kcal/mol. Therefore, we suggest that Tyr-187 and Pro-193 in the alpha 7 receptor are in proximity to Arg-33 in alpha -Cbtx. Sometimes, coupling values may increase when different types of mutations are introduced at a receptor residue position (16, 17, 29). For example, coupling energies of 0.6 and 1.7 kcal/mol were observed between Y190F/R33E and Y190T/R33E, respectively, at the alpha gamma interface of the muscular alpha  subunit (16). Therefore, we explored a possible mutation-type effect using various mutations at receptor position 187. However, no detectable alpha -Bgtx binding was observed with the different mutants obtained (Y187T, Y187A, Y187R, and Y187K) (Table II), suggesting that the presence of an aromatic residue at this position is crucial either for toxin binding or for correct receptor expression. Finally, no coupling was seen between toxin Arg-33 and alpha 7 receptor Trp-54, Leu-118, and Asp-163, suggesting, at least from these preliminary results, that there is no interaction between Arg-33 and these receptor residues. Similarly, Tyr-187 on the receptor does not seem to interact with Phe-65 on the toxin.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Previous studies demonstrated that a long chain toxin can bind with high affinity to both the muscular type AChR and the neuronal alpha 7-AChR (8). In this work, we have used a mutational approach to search for residues that are neuron-specific. It is always difficult to establish a cutoff value above which a decrease in binding affinity, as caused by a mutation, reflects involvement of the mutated residue in a binding process. However, from various comparative studies of structural and mutational analyses of protein-protein complexes, it was suggested that a mutation causing a variation in binding energy of >1 kcal/mol may reflect such an involvement (30-32).

The Site by Which alpha -Cbtx Binds to the Neuronal alpha 7 Receptor-- Ten residues of alpha -Cbtx (Trp-25, Cys-26-Cys-30, Asp-27, Ala-28, Phe-29, Arg-33, Lys-35, Arg-36, and Phe-65) are mutation-sensitive and may therefore constitute the surface by which the toxin interacts with the neuronal alpha 7 receptor. This delineation is further supported by the observation that numerous surrounding residues in loop I (from Phe-4 to Asp-13), at the base of loop II (Tyr-21, Lys-23, and Asp-38), and in loop III (Thr-47, Lys-49, and Asp-53) are mutation-insensitive and therefore probably excluded from the binding surface (see Fig. 4B and Table I). With the exception of Phe-65 in the C-terminal tail, all the functionally important residues of the toxin belong to the toxin loop II. Six of these residues (Trp-25, Asp-27, Ala-28, Phe-29, Arg-33, and Arg-36) have their side chain orientated toward the concave face of the large toxin beta -sheet, whereas the side chains of Lys-35 and Cys-26-Cys-30 are accessible from the other face. This organization gives the impression that the toxin loop II interacts with receptor residues that form a sort of groove. The additional Phe-65 is located relatively far from the binding region displayed by the central finger and hence may further stabilize the toxin-receptor complex. It is also noticeable that the receptor-binding site includes a cluster of three positively charged residues, Arg-33, Lys-35, and Arg-36, with Arg-33 probably playing the most critical binding role. However, we must note that Arg-33 was mutated to Glu, whereas the two other residues were mutated to alanine, and we cannot exclude the possibility that the charge inversion might have amplified an unfavorable effect on toxin binding. In any case, the positively charged cluster is surrounded by numerous hydrophobic side chains, including three aromatic residues (Trp-25, Phe-29, and Phe-65) and, to a lesser extent, the aliphatic residue Ala-28. Only one negatively charged residue (Asp-27) seems to be important, although its negative character is not functionally determinant since mutation D27N had no effect on the stability of the toxin-receptor complex. Therefore, the determinant that ensures toxin binding to the alpha 7 receptor is compactly located on the toxin central loop, except for Phe-65, with three positively charges surrounded by a hydrophobic ring.

Molecular Basis for the Dual Selectivity of alpha -Cbtx-- A major goal of this study was to understand how alpha -Cbtx can recognize two subsets of AChRs. To this purpose, we compared the data reported in this paper with those describing the residues through which alpha -Cbtx also binds to a muscular type (Torpedo) AChR (13). The comparative data are compiled in Fig. 3 and show the effects of the same mutations on the differential binding energy for both neuronal and Torpedo AChRs. Although this comparison should be considered with caution due to the different competition methods used with both receptors, a qualitative comparison revealed two groups of interacting residues: first, residues for which at least one mutation affects toxin binding affinity for both types of AChRs, and second, those for which a mutation affects binding affinity for only one type of receptor. In this comparison, we have considered the mutational effects on one or both of the two physically different toxin-binding sites that are present in the Torpedo receptor. For sake of clarity, a summary of the data from Fig. 3 is shown in Fig. 4, with all excluded residues displayed in green and those that are important for binding to one and/or both receptors in yellow, orange, and red.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 3.   Comparison of the difference in the binding energy for the alpha -Cbtx mutants on the muscular and alpha 7 receptors. Delta Delta G = RT ln(Kd(mut)/Kd(wt)). Dissociation constants of alpha -Cbtx mutants were obtained from equilibrium competition experiments using 3H-labeled alpha -toxin as a tracer on the Torpedo receptor (12) or using the inhibition of the initial rate of 125I-Bgtx on the alpha 7 receptor.


View larger version (59K):
[in this window]
[in a new window]
 
Fig. 4.   Comparison of the functional sites by which alpha -Cbtx interacts with the Torpedo (A) and alpha 7 (B) receptor subtypes. The concave toxin face is shown in both cases. Residues whose mutations caused an affinity decrease <5-fold are in green, between 5- and 9-fold in yellow, between 10- and 100-fold in orange, and >100-fold in red.

The site by which the toxin recognizes the Torpedo AChR covers a surface of ~900 Å2 that crosses the concave face of the toxin on loops II and III and part of the C-terminal tail. The neuronal functional site covers a similar surface of 800 Å2 spread on both the concave and convex faces of loop II and the C-terminal tail. The two binding sites therefore display similarities and marked differences.

Six toxin residues were mutation-sensitive to both receptors and caused a differential binding energy of at least 1 kcal/mol. These are Trp-25, Asp-27, Phe-29, Arg-33, Arg-36, and Phe-65, which can be divided into two groups. First, mutations at Trp-25, Asp-27, and Arg-33 comparably affect the binding to both receptors (Fig. 3). Thus, mutation R33E always caused the largest effect, with the binding energy differences being ~3.5 kcal/mol for both receptors. Asp-27 may also play a major binding role in both cases since a change in binding energy of ~2 kcal/mol was observed for both receptors in mutation D27R. In both cases, however, the negative charge is not the important binding factor since mutation D27N did not affect binding to either receptor. Although its importance is more moderate, Trp-25 may also play a comparable role in binding to either receptor. The three mutations introduced at this position suggest that the presence of an aromatic side chain at this position could be an important binding element. Therefore, the mutation data suggest that Arg-33, Asp-27, and Trp-25 may play similar binding functions for the Torpedo and neuronal AChRs and hence might recognize similar determinants on both receptors.

Mutations at Phe-29, Arg-36, and Phe-65 also caused affinity decreases for both receptors, but the observed effects were different in terms of binding energy. Mutation F29A caused a large affinity decrease for the neuronal receptor only, whereas F29L caused a strong effect regarding the Torpedo receptor. Also, mutations R36A and F65A caused much larger effects on toxin binding to the neuronal receptor. Therefore, if these three residues are clearly important for the toxin to bind to both receptors, their differential binding contribution suggests that they recognize either distinct receptor determinants or the same determinants, but differently.

Further indicating that the toxin-binding sites are not identical in the two receptors, we found a number of residues whose mutations affect only one of the two AChRs. Thus, Ala-28, Cys-26-Cys-30, and Lys-35 are selectively involved in binding to the alpha 7 receptor, even if the mutations introduced at these positions induce only moderate affinity decreases. We note that Lys-35 and the disulfide bond Cys-26-Cys-30 are on the convex face of the toxin, which is not considered to be important for curarimimetic toxins to bind to the muscular AChR (13-15). These residues may therefore interact with determinants that are present in the alpha 7-AChR, but not in the Torpedo AChR. Interestingly enough, the homologous fifth disulfide bond of the neuronal kappa -neurotoxins is also involved in the binding to the neuronal alpha 3beta 2-AChR (33), suggesting that neuronal AChRs might possess a common determinant recognized by the fifth disulfide bond of long chain three-fingered toxins.

Two mutation-sensitive positions are clearly Torpedo AChR-specific. These are Lys-23 and Lys-49. More precisely, mutations at these positions affect the low affinity binding site of the muscular receptor, but not its high affinity binding site. Therefore, the two highly conserved Lys-23 and Lys-49 residues seem to be important for the curarimimetic toxins to recognize specific determinants at the low affinity binding site of the muscular receptor, perhaps at the interface of the alpha gamma subunits (16, 23).

In summary, alpha -Cbtx commonly "uses" Trp-25, Asp-27, Phe-29, Arg-33, Arg-36, and Phe-65 to bind to both the neuronal alpha 7 and muscular type AChRs, with some of them (Phe-29, Arg-36, and Phe-65) contributing differentially to the binding to both receptors. The common functional residues are assisted by Ala-28, Cys-26-Cys-30, and Lys-35, which may bind to alpha 7-specific AChR determinants, and by Lys-23 and Lys-49, which may recognize muscular-specific AChR determinants. Thus, this work unambiguously reveals that a toxin recognizes two subtypes of AChRs using a common binding core assisted by additional residues that bind to determinants that are likely to be specific to each receptor subtype. This is a scenario that may be general for most, if not all, toxin-receptor interactions, including those from sea anemones (34) and scorpions (31, 35) that bind to various subtypes of potassium channels.

Whereas both long and short chain curarimimetic toxins bind with high affinities to muscular type AChRs (2), only the long chain toxins also bind with high affinity to the neuronal alpha 7 receptor (8). The data reported in this paper may explain the origin of this differential behavior: alpha -Cbtx and most long chain curarimimetic toxins, but not short chain toxins (2), possess residues that may bind to alpha 7-specific AChR determinants, including Ala-28, the disulfide bond between residues 26 and 30, and Lys-35.

Toxin-binding Sites Include Homologous Regions of the Muscular AChR and the alpha 7-AChR-- Since Trp-25, Asp-27, and Arg-33 are comparably important for alpha -Cbtx to bind to both neuronal and muscular AChRs, we wondered whether these residues recognize homologous determinants in both receptors. To explore this possibility, we investigated whether at least one of these residues interacts with a homologous residue in both receptors. In this respect, Arg-33 in the toxin was particularly appealing for two reasons. First, its mutation to Glu causes the largest alpha -Cbtx affinity decrease for both the Torpedo (13) and neuronal (this work) receptors, suggesting that this residue is most crucial for binding to both receptors. Second, Arg-33 of another curarimimetic toxin was shown to interact with Val-188 and Tyr-190 located on the alpha  subunit of the mouse muscular AChR (16). Using double mutant cycle methodology, we found a coupling energy of -0.71 kcal/mol for the mutant pair R33E/Y187F. This value is clearly above the numerous background values that probably reflect the absence of coupling (0.15 kcal/mol). Also, the value of -0.71 kcal/mol fits nicely within the range (0.35-1.2 kcal/mol) previously identified to characterize interactions occurring between charged and uncharged residues separated by 4-7 Å (26). Although we are unable to estimate the distance separating Arg-33 in alpha -Cbtx and Tyr-187 in the alpha 7 receptor, our data suggest that they are close to each other. Since a similar situation was observed between Arg-33 of another curarimimetic toxin and the homologous Tyr-190 of a muscular type receptor (16), it is likely that toxin binding to neuronal and muscular receptors takes place in homologous regions.

To better define the region of the neuronal receptor that is recognized by alpha -Cbtx, we proceeded to further double mutant cycle analyses. The mutant pair P193A/R33E was characterized by a coupling energy of -0.86 kcal/mol, which also suggests a proximity between Arg-33 in the toxin and Pro-193 in the receptor. The low coupling values (0.15 kcal/mol) observed for all other mutant pairs suggest that Arg-33 is not close to Trp-54, Leu-118, and Asp-163, in contrast to what has been observed in a homologous situation between another curarimimetic toxin and the mouse muscular AChR (17). Therefore, although occurring in homologous regions of neuronal and muscular receptors, toxin binding does not involve identical determinants. Finally, the low coupling value (Delta Delta Gint = 0.03 kcal/mol) that characterized the pair Y187F/F65A also suggests no proximity between Tyr-187 and Phe-65, a finding that is in agreement with the observation that in alpha -Cbtx, Arg-33 and Phe-65 are separated by 15 Å, making it unlikely that both residues could interact simultaneously with Tyr-187.

In conclusion, this study shows that a long chain toxin from snake venom binds to homologous, although not identical, regions of two AChR subtypes using a common core of amino acids assisted by a number of additional subtype-specific residues. We are now currently investigating how these data can be exploited to confer new specificity profiles to the toxin.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 33-1-69083803; Fax: 33-1-69089071; E-mail: andre.menez@cea.fr or denis.servent{at}cea.fr.

Published, JBC Papers in Press, June 13, 2000, DOI 10.1074/jbc.M909746199

    ABBREVIATIONS

The abbreviations used are: AChRs, nicotinic acetylcholine receptors; Cbtx, cobratoxin; Bgtx, bungarotoxin; HEK, human embryonic kidney; 5-HT3, 5-hydroxytryptamine type 3.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Changeux, J. P., Kasai, M., and Lee, C. Y. (1970) Proc. Natl. Acad. Sci. U. S. A. 67, 1241-1247
2. Endo, T., and Tamiya, N. (1991) in Snake Toxins (Harvey, A. L., ed) , pp. 165-222, Pergamon Press Inc., New York
3. Basus, V. J., Song, G., and Hawrot, E. (1993) Biochemistry 32, 12290-12298
4. Low, B. W., and Corfield, P. W. R. (1986) Eur. J. Biochem. 161, 579-587
5. Tsernoglou, D., and Petsko, G. A. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 971-974
6. Walkinshaw, M. D., Saenger, W., and Maelicke, A. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 2400-2404
7. Zinn Justin, S., Roumestand, C., Gilquin, B., Bontems, F., Ménez, A., and Toma, F. (1992) Biochemistry 31, 11335-11347
8. Servent, D., Winckler-Dietrich, V., Hu, H. Y., Kessler, P., Drevet, P., Bertrand, D., and Ménez, A. (1997) J. Biol. Chem. 272, 24279-24286
9. Ménez, A., and Servent, D. (1997) in Guidebook to Protein Toxins and Their Use in Cell Biology (Rapuolli, R. , and Montecucco, C., eds) , pp. 194-195, Oxford University Press, New York
10. Wüster, W. (1996) Toxicon 34, 399-406
11. Le Goas, R., Laplante, S. R., Mikou, A., Delsuc, M. A., Guittet, E., Robin, M., Charpentier, I., and Lallemand, J. Y. (1992) Biochemistry 31, 4867-4875
12. Betzel, C., Lange, G., Pal, G. P., Wilson, K. S., Maelicke, A., and Saenger, W. (1991) J. Biol. Chem. 266, 21530-21536
13. Antil, S., Servent, D., and Ménez, A. (1999) J. Biol. Chem. 274, 34851-34858
14. Pillet, L., Tremeau, O., Ducancel, F., Drevet, P., Zinn-Justin, S., Pinkasfeld, S., Boulain, J. C., and Ménez, A. (1993) J. Biol. Chem. 268, 909-916
15. Trémeau, O., Lemaire, C., Drevet, P., Pinkasfeld, S., Ducancel, F., Boulain, J. C., and Ménez, A. (1995) J. Biol. Chem. 270, 9362-9369
16. Ackermann, E. J., Ang, E. T. H., Kanter, J. R., Tsigelny, I., and Taylor, P. (1998) J. Biol. Chem. 273, 10958-10964
17. Osaka, H., Malany, S., Molles, B. E., Sine, S. M., and Taylor, P. (2000) J. Biol. Chem. 275, 5478-5484
18. Drevet, P., Lemaire, C., Gasparini, S., ZinnJustin, S., Lajeunesse, E., Ducancel, F., Pinkasfeld, S., Courcon, M., Tremeau, O., Boulain, J. C., and Ménez, A. (1997) Protein Expression Purif. 10, 293-300
19. Eiselé, J. L., Bertrand, S., Galzi, J. L., Devillers-Thiéry, A., Changeux, J. P., and Bertrand, D. (1993) Nature 366, 479-483
20. Corringer, P. J., Galzi, J. L., Eiselé, J. L., Bertrand, S., Changeux, J. P., and Bertrand, D. (1995) J. Biol. Chem. 270, 11749-11752
21. Servent, D., Lamthanh, H., Antil, S., Bertrand, D., Corringer, P. J., Changeux, J. P., and Ménez, A. (1998) J. Physiol. (Paris) 92, 107-111
22. Weber, M., and Changeux, J. P. (1974) Mol. Pharmacol. 10, 15-34
23. Ackermann, E. J., and Taylor, P. (1997) Biochemistry 36, 12836-12844
24. Rosenthal, J. A., Levandoski, M. M., Chang, B., Potts, J. F., Shi, Q.-L., and Hawrot, E. (1999) Biochemistry 38, 7847-7855
25. Tsigelny, I., Sugiyama, N., Sine, S. M., and Taylor, P. (1997) Biophys. J. 73, 52-66
26. Schreiber, G., and Fersht, A. R. (1995) J. Mol. Biol. 248, 478-486
27. Hidalgo, P., and MacKinnon, R. (1995) Science 268, 307-310
28. Otzen, D. E., and Fersht, A. R. (1999) Protein Eng. 12, 41-45
29. Osaka, H., Malany, S., Kanter, J. R., Sine, S. M., and Taylor, P. (1999) J. Biol. Chem. 274, 9581-9586
30. Prasad, L., Sharma, S., Vandonselaar, M., Quail, J. W., Lee, J. S., Waygood, E. B., Wilson, K. S., Dauter, S., and Delbaere, L. T. G. (1993) J. Biol. Chem. 268, 10705-10708
31. Goldstein, S. A. N., Pheasant, D. J., and Miller, C. (1994) Neuron 12, 1377-1388
32. Ducancel, F., Mérienne, K., Fromen-Romano, C., Trémeau, O., Pillet, L., Drevet, P., Zinn-Justin, S., Boulain, J. C., and Ménez, A. (1996) J. Biol. Chem. 271, 31345-31353
33. Grant, G. A., Luetje, C. W., Summers, R., and Xu, X. L. (1998) Biochemistry 37, 12166-12171
34. Alessandri-Haber, N., Lecoq, A., Gasparini, S., Grangier-Macmath, G., Jacquet, G., Harvey, A. L., de Medeiros, C., Rowan, E. G., Gola, M., Ménez, A., and Crest, M. (1999) J. Biol. Chem. 274, 35653-35659
35. Stampe, P., Kolmakova-Partensky, L., and Miller, C. (1994) Biochemistry 33, 443-450


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
E. N. Lyukmanova, Z. O. Shenkarev, A. A. Schulga, Y. S. Ermolyuk, D. Yu. Mordvintsev, Y. N. Utkin, M. A. Shoulepko, R. C. Hogg, D. Bertrand, D. A. Dolgikh, et al.
Bacterial Expression, NMR, and Electrophysiology Analysis of Chimeric Short/Long-chain {alpha}-Neurotoxins Acting on Neuronal Nicotinic Receptors
J. Biol. Chem., August 24, 2007; 282(34): 24784 - 24791.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-W. Chi, K.-H. Park, J.-E. Suk, B. M. Olivera, J. M. McIntosh, and K.-H. Han
Solution Conformation of {alpha}A-conotoxin EIVA, a Potent Neuromuscular Nicotinic Acetylcholine Receptor Antagonist from Conus ermineus
J. Biol. Chem., October 24, 2003; 278(43): 42208 - 42213.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. Mourier, S. Dutertre, C. Fruchart-Gaillard, A. Menez, and D. Servent
Chemical Synthesis of MT1 and MT7 Muscarinic Toxins: Critical Role of Arg-34 in Their Interaction with M1 Muscarinic Receptor
Mol. Pharmacol., January 1, 2003; 63(1): 26 - 35.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Nirthanan, E. Charpantier, P. Gopalakrishnakone, M. C. E. Gwee, H.-E. Khoo, L.-S. Cheah, D. Bertrand, and R. M. Kini
Candoxin, a Novel Toxin from Bungarus candidus, Is a Reversible Antagonist of Muscle (alpha beta gamma delta ) but a Poorly Reversible Antagonist of Neuronal alpha 7 Nicotinic Acetylcholine Receptors
J. Biol. Chem., May 10, 2002; 277(20): 17811 - 17820.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Moise, A. Piserchio, V. J. Basus, and E. Hawrot
NMR Structural Analysis of alpha -Bungarotoxin and Its Complex with the Principal alpha -Neurotoxin-binding Sequence on the alpha 7 Subunit of a Neuronal Nicotinic Acetylcholine Receptor
J. Biol. Chem., March 29, 2002; 277(14): 12406 - 12417.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Fruchart-Gaillard, B. Gilquin, S. Antil-Delbeke, N. Le Novere, T. Tamiya, P.-J. Corringer, J.-P. Changeux, A. Menez, and D. Servent
Experimentally based model of a complex between a snake toxin and the alpha 7 nicotinic receptor
PNAS, February 20, 2002; (2002) 42699899.
[Abstract] [Full Text] [PDF]